FYN
MOLECULAR TARGETFYN proto-oncogene, Src family tyrosine kinase
FYN (FYN proto-oncogene, Src family tyrosine kinase) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting FYN
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Rosmarinic Acid | 1.61 | 4 |
| 2 | Genistein | 1.10 | 2 |
| 3 | Dasatinib | 1.10 | 2 |
| 4 | egcg | 0.69 | 1 |
| 5 | Acetic Acid Product of | 0.69 | 1 |
| 6 | Crizotinib | 0.69 | 1 |
| 7 | kenpaullone | 0.69 | 1 |
| 8 | Sorafenib | 0.69 | 1 |
| 9 | tyrphostin ag 1478 | 0.69 | 1 |
About FYN as a Drug Target
FYN (FYN proto-oncogene, Src family tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented FYN interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
FYN inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.